

Pharmacy Prior Authorization Form

Fax completed form to: 877.974.4411 toll free, or 616.942.8206

This form applies to: Commercial (Traditional) Commercial (Individual/Optimized)

Medicaid

This request is: Urgent (life threatening) Non-Urgent (standard review)

Urgent means the standard review time may seriously jeopardize the life or health of the patient or the patient's ability to regain maximum function.

Alunbrig[®] (brigatinib)

Member

Last Name: _____ First Name: _____

ID #: _____ DOB: _____ Gender: _____

Primary Care Physician: _____

Requesting Provider: _____ Prov. Phone: _____ Prov. Fax: _____

Provider Address: _____

Provider NPI: _____ Contact Name: _____

Provider Signature: _____ Date: _____

Product Information

New Request Continuation Request

Drug product: Alunbrig 30 mg tablet

Start date (or date of next dose): _____

Date of last dose (if applicable): _____

Dosing frequency: _____

Oral oncology partial fill program

Each fill of Alunbrig is limited to a 14 day supply. Patients are responsible for applicable deductible and copayments.

Precertification Requirements

For this drug to be covered, the patient must meet the following criteria:

1. Diagnosis of anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC)
2. Had disease progression or was intolerant to crizotinib (Xalkori)
3. Must have tried alectinib (Alecensa)

Priority Health Precertification Documentation

A. What condition is this drug being requested for?

ALK-positive, metastatic non-small cell lung cancer

Other – the patient's condition is: _____

Rationale for use: _____

B. Has the patient had disease progression or intolerance to Xalkori?

Yes; date and duration of trial: _____

No; rationale for use: _____

C. Has the patient had disease progression or intolerance to Alecensa?

Yes; date and duration of trial: _____

No; rationale for use: _____

Additional information

Requests for any condition not listed as covered require evidence of current medical literature that substantiates the drug's efficacy or that recognized oncology organizations generally accept the treatment for the condition.